Anthony J. Perissinotti

Anthony J. Perissinotti

Auto-generated profile, based on publicly available information

Anthony J. Perissinotti

Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
LTLaura A Tang
Laura A Tang
BMBernard L Marini
Bernard L Marini
LBLydia Benitez
Lydia Benitez
JNJerod L Nagel
Jerod L Nagel
MMMarisa Miceli
Marisa Miceli
APAnthony J Perissinotti
Anthony J Perissinotti
Posaconazole is the prophylactic antifungal of choice for patients with haematological malignancies at high risk of invasive fungal infections (IFIs). Studies have demonstrated that subtherapeutic concentrations of posaconazole are associated with breakthrough fungal infections and specific risk factors for subtherapeutic troughs associated with the suspension formulation have been identified. However, these risk factors have not been evaluated in a large patient population with the recently approved tablet formulation. To determine the risk factors for subtherapeutic posaconazole troughs associated with the tablet formulation in patients receiving posaconazole as IFI prophylaxis. From 1 February 2013 to 31 March 2015 all posaconazole serum trough concentrations were evaluated. A total of 157 patients receiving posaconazole tablet for prophylaxis during induction therapy for haematological malignancies and allogeneic stem cell transplant recipients with graft-versus-host disease were included for analysis. Overall, 28 patients (18%) had subtherapeutic troughs (<700 ng/mL). Patients were more likely to have subtherapeutic troughs if they had diarrhoea (n = 24; 83%) (P < 0.001), were receiving a proton pump inhibitor (n = 27; 93%) (P = 0.016) and weighed >90 kg (n = 14; 48%) (P = 0.047). While the posaconazole tablet has provided more consistent therapeutic concentrations when compared with the suspension there may still be a role for therapeutic drug monitoring (TDM). These results may guide us to a specific population in which TDM is necessary to identify subtherapeutic troughs.

28 June 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
TWTaylor M. Weis
Taylor M. Weis
BMBernard L. Marini
Bernard L. Marini
DBDale L. Bixby
Dale L. Bixby
APAnthony J. Perissinotti
Anthony J. Perissinotti

1 September 2017 in Blood Reviews
Verified
Journal Article
Closed access
BMBernard L. Marini
Bernard L. Marini
APAnthony J. Perissinotti
Anthony J. Perissinotti
DBDale L. Bixby
Dale L. Bixby
JBJulia Brown
Julia Brown
PBPatrick W. Burke
Patrick W. Burke

17 May 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
BMBernard L. Marini
Bernard L. Marini
JBJulia Brown
Julia Brown
LBLydia Benitez
Lydia Benitez
EWEmily Walling
Emily Walling
RHRaymond J. Hutchinson
Raymond J. Hutchinson
APAnthony J. Perissinotti
Anthony J. Perissinotti
The availability of Erwinia Asparaginase has been limited across the world due to manufacturing shortages or for some countries due to the high acquisition cost, putting patients at risk for inferior outcomes. This manuscript provides guidance on how to manage hypersensitivity reactions and utilize therapeutic drug monitoring (TDM) to conserve and limit Erwinia use. The clinical and financial impact of a multidisciplinary committee are also discussed. Faced with a global Erwinia shortage, a multidisciplinary asparaginase allergy committee was created to review all hypersensitivity reactions to asparaginase therapy, staff education was performed on the management of asparaginase hypersensitivity reactions, an institution-wide premedication policy was mandated, and standardized guidelines were created for TDM. This multidisciplinary approach reduced the PEG-asparaginase to Erwinia switch rate from 21% (35 of 163) to 7% (10 of 134) (p = .0035). A multifaceted approach can safely maintain patients on PEG-asparaginase and conserve Erwinia for patients who need it most.

1 July 2018 in Leukemia Research
Verified
Journal Article
Closed access
VVVera Vulaj
Vera Vulaj
APAnthony J. Perissinotti
Anthony J. Perissinotti
JUJames R. Uebel
James R. Uebel
VNVictoria R. Nachar
Victoria R. Nachar
GSGianni B. Scappaticci
Gianni B. Scappaticci
BMBernard L. Marini
Bernard L. Marini

5 June 2017 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RDRyan K DasGupta
Ryan K DasGupta
BMBernard L Marini
Bernard L Marini
JRJoslyn Rudoni
Joslyn Rudoni
APAnthony J Perissinotti
Anthony J Perissinotti
Aim: Novel immunotherapies have generated high response rates and unique adverse effects among patients with relapsed or refractory acute lymphoblastic leukemia. Therapies engaging endogenous T-cells against acute lymphoblastic leukemia are emerging for children and adults with various poor prognostic factors, thus accurate knowledge of immunotherapies is necessary for their effective implementation in the future. In this review, we evaluate clinical trial data regarding chimeric antigen receptor T-cells and blinatumomab, for the treatment of relapsed or refractory acute lymphoblastic leukemia. Summary: In the relapsed or refractory setting, response rates rapidly diminish after subsequent lines of chemotherapy and cumulative toxicities may cause significant patient harm. Immunotherapies provide an approach to improve response rates and minimize traditional toxicities via novel mechanisms of action. Two therapies targeting CD19 antigens expressed on B-cell acute lymphoblastic leukemia lineages, chimeric antigen receptor T-cells, and blinatumomab have induced complete remissions among high-risk patient populations, especially those refractory to multiple therapies. Adverse effects such as cytokine release syndrome and neurologic sequelae remain serious precautions of each therapy. Conclusion: Knowledge of immunotherapy mechanisms and clinical outcomes associated with immunotherapies is critical for the optimization of treating patients with relapsed or refractory acute lymphoblastic leukemia. Future use of chimeric antigen receptor T-cells and blinatumomab demands proper assessment of a patient’s disease and treatment history in addition to unique monitoring and supportive care interventions.